Tehran University of Medical Sciences International Journal of Hematology-Oncology and Stem Cell Research 2008-2207 16 3 2022 07 09 157 163 Roya Irani Department of Biology, Islamic Azad University, Tabriz Branch, Tabriz, Iran Masoud Maleki Department of Biology, Islamic Azad University, Tabriz branch, Tabriz, Iran Vida Vahdani Kia Department of Biology, Islamic Azad University, Tabriz branch, Tabriz, Iran Esmaeil Safavi Department of Basic Sciences, Biotechnology Research Center, Tabriz Branch, Islamic Azad University, Tabriz, Iran Negin Sadi Khosroshahi Department of Biology, Faculty of Basic Sciences, Azarbaijan Shahid Madani University, Tabriz, Iran 2021 03 29 2021 10 23 Background: Prostate cancer is the second most common cancer in the male that affects the health, social and economic life of person. Different compounds such as Wharton jelly, have been used to treat prostate cancer. Wharton jelly is a tissue rich in cells with mesenchymal morphology. Wharton jelly compound inhibited the growth of various cancer cells, including ovarian, osteosarcoma, breast, and prostate cancers, and also reduced the expression of CXCR4 and VLA-4 genes involved in the metastasis process. Materials and Methods: To do this research, Wharton jelly stem cells and DU145 cancer cell line were cultured. After cell culture, the effect of Wharton jelly on this cell line was evaluated by scratching and MTT assay. The expression of CXCR4 and VLA-4 genes was also evaluated by Real-time PCR. Results: The results of MTT and Scratching tests showed that Wharton jelly inhibited the growth of DU145 cancer cells and also decreased the expression level of CXCR4 and VLA-4 genes. Conclusion: The results of this study showed that Wharton jelly can be considered as an effective compound for decreasing metastasis of prostate cancer. https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/view/1593 https://ijhoscr.tums.ac.ir/index.php/ijhoscr/article/download/1593/941